Experts say the new at the Oxford University developed Vaccine R21/Matrix-M versus Malaria could drastically reduce the number of children dying from the infectious disease. University scientists already have a deal with a serum institute in In the event that completed, which is expected to produce 200 million doses of the vaccine annually from 2023.
Four doses of Matrix-M are required for a complete vaccination. This would allow enough vaccine doses to be produced annually to cover the WHO to vaccinate an estimated 25 million children in malaria-affected areas.
Die Non-profit-Organisation Malaria No More says recent advances could mean “no more children dying of malaria in our lifetime.” According to the WHO, there were 241 million cases of malaria in 2020 627.000 Malariatote – most came from sub-Saharan Africa, 80 percent were children.
Probably more effective than previous malaria vaccine
in an im Lancet journal In the study published, the university’s scientists report that in children who were given four higher doses of the vaccine, the vaccine was 80 percent effective after twelve months. For those on a lower dose, 70 percent. The 400 children who took part in the study live in Burkina Faso and received the vaccines before the peak malaria season. Another study with more participants is currently underway.
If the ongoing study confirms the previous results on the effectiveness of the malaria vaccine, it would be better and longer effective than the one approved just last year Mosquirix (RTS,S), which was the first approved vaccine ever and is 63 percent effective. The pharmaceutical company produces Mosquirix GSK currently 15 million annually by 2028.
Oxford scientist Adrian Hill says Mosquirix, which has been in development since the 1980s, paved the way for the new vaccine. According to Hill, the cost of producing a dose of Matrix-M is only a few dollars.